Sanofi suffers multiple sclerosis setback


French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration (FDA) rejected its multiple sclerosis drug Lemtrada (alemtuzumab). The agency said that its rejection of alemtuzumab was the result of poor Phase III clinical trial design and side effects that outweigh the potential benefits.

When Sanofi bought Genzyme for more than $20 billion (£12 billion) in February 2011, additional milestone payments were agreed, depending on the success of alemtuzumab. The monoclonal antibody was approved to treat multiple sclerosis in the EU in September 2013, leading to expectations that the FDA would follow suit in the US.

Without the US market, Lemtrada is very unlikely to meet sales targets, and consequently Sanofi’s share price fell by 1.1%. Furthermore, one US law firm is launching a class action on behalf of investors, claiming the French company made misleading statements about the prospects for alemtuzumab.

In a press release, a spokesperson for Genzyme stated that they strongly disagree with the conclusions and plan to appeal against the FDA’s decision.


Related Content

2012 pharma industry roundup

3 January 2013 Business

news image

What were the bigger stories? And how did the industry fare overall?

Sanofi to buy Genzyme in $20 billion deal

17 February 2011 News Archive

news image

Sanofi-Aventis wins over Genzyme board with $1.5 billion increase to August 2010 bid

Most Read

Wind-powered lighting is almost a breeze

13 August 2014 Research

news image

Mechanoluminescent materials seen in a new light

Knock-out theory puts new spin on general anaesthesia

12 August 2014 Research

news image

Anaesthetics effect on proteins' electronic structure could explain mystery of how diverse molecules can cause unconsciousnes...

Most Commented

Why can we walk on custard?

12 July 2012 Research

news image

Scientists take a closer look at how shear-thickening fluids respond to impacts

Photon pinball identifies chemicals from afar

13 August 2014 Research

news image

Samples turned into random Raman lasers beam their secrets from over a kilometre away